Abstract：
:Bone marrow (BM) angiogenesis is increased in multiple myeloma and is an important prognostic factor. However, prior studies were mainly done on patients receiving conventional chemotherapy and there is limited data on its prognostic value in patients undergoing high-dose therapy (HDT) as initial therapy. We studied BM angiogenesis in terms of microvessel density (MVD) in 88 newly diagnosed patients, who were uniformly treated, with 3-4 cycles of induction chemotherapy followed by HDT. We examined if MVD at diagnosis was predictive of response to induction therapy or to subsequent HDT. In addition, we also examined its prognostic value in these patients. The median MVD for primary refractory patients was 28 (range, 2-84) compared to 27 (range, 2-99) for responding patients (P=0.7). The median progression-free survival (PFS) was 21 months for those with high-grade angiogenesis compared to 42 months for those with low-grade angiogenesis, P=0.017. The median overall-survival (OS) from diagnosis was 40 months for those with high-grade angiogenesis and not yet reached, for those with low-grade angiogenesis, P=0.007. BM MVD at the time of initial diagnosis is an important prognostic factor for OS and PFS in patients undergoing autologous transplantation as frontline therapy for myeloma.
journal_name
Bone Marrow Transplantjournal_title
Bone marrow transplantationauthors
Kumar S,Gertz MA,Dispenzieri A,Lacy MQ,Wellik LA,Fonseca R,Lust JA,Witzig TE,Kyle RA,Greipp PR,Rajkumar SVdoi
10.1038/sj.bmt.1704555subject
Has Abstractpub_date
2004-08-01 00:00:00pages
235-9issue
3eissn
0268-3369issn
1476-5365pii
1704555journal_volume
34pub_type
杂志文章abstract：:The growing number of BMTs has increased interest in safe and standardized in vitro bone marrow processing techniques. We describe our experience with a rapid automated method for the isolation of mononuclear cells (MNC) from large volumes of bone marrow using a Fenwal CS-3000 cell separator without employing density ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1992-12-01 00:00:00
abstract：:We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1994-10-01 00:00:00
abstract：:A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1705665
更新日期：2007-06-01 00:00:00
abstract：:Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order t...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704711
更新日期：2005-01-01 00:00:00
abstract：:Three widely used viability assessments were compared: (1) membrane integrity of nucleated cells using trypan blue (TB) exclusion and a fluorometric membrane integrity assay (SYTO 13 and propidium iodide), (2) enumeration of viable CD34+ cells, and (3) clonogenic assay (granulocyte-macrophage colony-forming units, CFU...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704247
更新日期：2003-11-01 00:00:00
abstract：:Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：10.1038/sj.bmt.1700961
更新日期：1997-11-01 00:00:00
abstract：:The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702043
更新日期：1999-12-01 00:00:00
abstract：:Gene therapy is a novel approach under investigation for the treatment of genetic diseases, cancer and AIDS. Hematopoietic stem cells would be the target cell for correction of hemoglobinopathies, immune deficiencies and lysosomal storage diseases. Retroviral vectors derived from murine leukemia viruses have been used...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：
更新日期：1996-12-01 00:00:00
abstract：:Among 145 consecutive patients undergoing bone marrow transplantation (BMT) for leukemia or aplastic anemia. 30 (21%) were found positive for hepatitis B surface antigen (HBsAg) in serum either before or after BMT. Their serologic profile and clinical outcome are described. Nine out of 30 patients were HBsAg positive ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1990-07-01 00:00:00
abstract：:Primitive haemopoietic cells are required for studies in both the clinical and research fields and a number of systems have been developed to facilitate isolation of these haemopoietic cell populations. We have analysed the results from several European centres using positive selection of CD34+ cells from haemopoietic...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,多中心研究
doi：10.1038/sj.bmt.1701789
更新日期：1999-06-01 00:00:00
abstract：:In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/s41409-020-0956-8
更新日期：2020-09-01 00:00:00
abstract：:The Cleveland Clinic blood and marrow transplant program has routinely performed 'backup' autologous harvests in unrelated recipients with hematological malignancies in remission, lymphoma without marrow involvement and CML in chronic phase. We reviewed all adult or cord unrelated donor (URD) transplants performed fro...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2009.95
更新日期：2010-01-01 00:00:00
abstract：:Diarrhea in marrow transplant recipients is a frequent complication attributable to non-infectious events such as acute GVHD or infectious events such as viral gastroenteritis. Rotavirus and enteric adenovirus are the most frequent viral pathogens. To determine the frequency of these infections, we prospectively exami...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1993-12-01 00:00:00
abstract：:To determine the effect of growth factor mobilization on the expression of adhesion molecules, we compared CD34+ progenitor cell (PC) populations from steady-state bone marrow (BM) with granulocyte-macrophage colony-stimulating factor (GM-CSF)-mobilized apheresis products (peripheral blood stem cell (PSC)) using flow ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1700814
更新日期：1997-06-01 00:00:00
abstract：:The cardiovascular risk of concurrent coronary artery disease in patients undergoing bone marrow transplantation (BMT) is not well known. We present a case of a 32-year-old male Hodgkin's disease patient with prior chemotherapy and radiotherapy, who underwent autologous BMT. His underlying single vessel coronary arter...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1994-05-01 00:00:00
abstract：:A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matche...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704172
更新日期：2003-09-01 00:00:00
abstract：:Seventy-nine patients with AML in CR1 received allo-SCT between May 2006 and May 2011, and the prognostic impact of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) mutation was evaluated in the context of other clinical prognostic factors. Patients with FLT3/ITD + AML had significantly inferior DFS (...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2012.88
更新日期：2012-12-01 00:00:00
abstract：:We evaluated a non-radiation containing preparative regimen for persons with myeloma receiving bone marrow (BM) or blood cell transplants. Twenty-three adults with advanced multiple myeloma (15 responsive to chemotherapy, 8 resistant) received cyclophosphamide 120 mg/kg and busulfan 14-16 mg/kg followed by the infusio...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：
更新日期：1994-07-01 00:00:00
abstract：:Patients with leukemia relapsing after allogeneic hematopoietic SCT have a dismal prognosis. A second SCT offers a further opportunity for cure, but has a high rate of treatment failure. To determine the utility of this option, we analyzed 59 consecutive patients relapsing after a myeloablative HLA-matched sibling T c...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：10.1038/bmt.2013.39
更新日期：2013-09-01 00:00:00
abstract：:Hemorrhagic cystitis (HC) is a common and sometimes life-threatening complication of hemopoietic cell transplantation (HCT) occurring in 7-52% of transplant recipients. In this setting it is usually either related to the use of cyclophosphamide or to a viral infection (BK, JC viruses and adenovirus type 11). Treatment...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1703954
更新日期：2003-05-01 00:00:00
abstract：:Although neurocognitive impairment has been established as a major issue among cancer survivors, the real-world consequences of this impairment are unclear. This study investigated the relationship between neurocognitive functioning and medication management ability over time among 58 patients treated with allogeneic ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2016.2
更新日期：2016-06-01 00:00:00
abstract：:Twenty eight Hungarian patients lacking a compatible related donor and their 61 HLA-A,B,DR serologically identical potential unrelated donors (selected from BMDW) were investigated in this study. Out of the 61 donor-recipient pairs only 7 (11,5%) proved to be HLA-identical at DNA level. Thirty one pairs (50,8%) differ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1998-12-01 00:00:00
abstract：:HLA-haploidentical hematopoietic SCT (HSCT) provides an opportunity for almost all patients who lack HLA-matched sibling donors. The donor availability can be increased by including the collateral related donors (CRDs). We compared clinical outcomes of patients with hematological malignancies, who underwent haploident...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2013.223
更新日期：2014-04-01 00:00:00
abstract：:Bulk cytotoxic T lymphocytes (CTL) were generated by in vitro stimulation of BMT donor lymphocytes with Philadelphia chromosome (Ph)-positive leukemic cells from an HLA-identical sibling patient. CTL were cytotoxic against the patient's leukemic cells as well as the EBV-lymphoblastoid cell line (EBV-LCL) generated fro...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1701856
更新日期：1999-07-01 00:00:00
abstract：:Ten patients with Ph+ chronic myeloid leukemia (CML) were treated with idarubicin, cytarabine and etoposide followed by G-CSF to harvest Ph-negative progenitor cells. Six were in first chronic phase (CP1), and four beyond CP1. Between two and six aphereses (median 3, total 36) were performed starting 9-26 days (median...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1996-01-01 00:00:00
abstract：:This study aimed to analyze the association between cytokine gene polymorphisms and outcome following allogeneic hematopoietic SCT (allo-HSCT). A total of 138 unrelated donor/recipient pairs who underwent allo-HSCT from 2001 to 2009 were tested for TNFA-1031 (T>C), -863 (C>A), -857 (C>T), -238 (G>A), TNFB+252 (A>G) an...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2010.135
更新日期：2011-03-01 00:00:00
abstract：:In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotox...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2015.119
更新日期：2015-09-01 00:00:00
abstract：:Fludarabine is a purine analog that has demonstrated significant activity in B-cell malignancies, including CLL. Fludarabine also possesses an immunosuppressive effect and is being used to prevent GVHD in hematopoietic stem cell transplantation. However, the molecular mechanism by which fludarabine inhibits immunoreac...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1705901
更新日期：2008-02-01 00:00:00
abstract：:We report two children who presented with cough and shortness of breath 7-8 months after a matched sibling stem cell transplant (SCT) for chronic myelogenous leukemia and myelodysplastic syndrome, respectively. Pulmonary function tests (PFTs) revealed severe airways obstruction (AO). However, radiographic investigatio...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1701425
更新日期：1998-10-01 00:00:00
abstract：:A 51-year-old patient with refractory CLL elected to participate in a trial of nonmyeloablative trans- plantation from an HLA-matched unrelated donor. He received low-dose fludarabine/TBI, with infusion of donor PBPC and cyclosporin (CsA)/MMF. Early post transplant he experienced explosive tumor growth with respirator...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1703293
更新日期：2001-12-01 00:00:00
